As the century comes to a close, it is hard to think of any major neurologic problem which is not better understood as a result of research or for which new therapies are either being contemplated or are already approved. This was certainly not the case when CNS began in the late 1970's. At that time, several patients, a few scientists and I cast our lot together to do something to change the dismal outlook for patients with incurable neurologic diseases. We thought then, as we do now, that there was too much seperation between patients and the people who work on their behalf. We were inclined to treat patients as colleagues rather than research subjects. This spirit has continued to this day. Given the restructuring of medicine, CNS may turn out to be an anomaly in an environment where corporations rather than doctors and patients determine how to spend health care dollars.
What is less unique now than in the past is our commitment to experimental treatment. Currently, almost every medical center is committted to experimental therapy. Although this may make it a more competitive environment for CNS, it augers well for patients who have the luxury of deciding which treatment program looks to be the most promising. If the past is any guide, things may not turn out to be as simple as one would like. As in the case of cancer, it takes time and insight to determine which combinations of drugs ultimately are the most effective. One can not help but wonder whether the same strategy will apply to the treatment of multiple sclerosis, ALS and other disorders. If it comes down to this, CNS may well continue to be at the forefront of innovation. Whether it be interferon, growth factors or glutamate blockers, we have been among the first to use them. The patients that come to us and the benefactors who have supported us have made this possible. To go forward, we need your continued support.
With best wishes,
Richard A. Smith, M.D.